Fed. Circ. Urged Not To Reverse Jazz’s Orange Book Delisting


By Kelly Lienhard (January 17, 2023, 9:40 PM EST) — Avadel CNS Pharmaceuticals LLC has asked the Federal Circuit to immediately remove patent protection for Jazz Pharmaceuticals’ narcolepsy drug even though Jazz is appealing a district court order to delist a patent for the treatment, arguing access to Avadel’s version of the drug would be “life-changing” for patients….

Latest Intelligence